fbpx Skip to main content

The Basics of Biotech

When:

May 4, 2020 8:30 amMay 5, 2020 4:30 pm (PDT)

Where:

Biocom – McGraw Conference Room
10996 Torreyana Road Suite 200
San Diego, California 92121

Registration Closed

Basics of Biotech is a comprehensive, two-day course meant to provide you with an overview of the development of biopharmaceuticals from the bench top to commercial scale manufacturing. The course will start with foundational basics and give a detailed overview of the entire process from discovery to commercialization. As an attendee, you will learn the science behind biotech products, the clinical research process, regulatory filings and scale-up for manufacturing. Different types of products, such as biologic drugs, biosimilars, personalized medicine, stem cell and regenerative medicine, will be outlined.

Learning Objectives:
Over two days, this interactive course will…
Explain the biotech processes, what they are and how they work
Explain the biotech lab, what it looks like and how it operates
Explain the biotech product development process
Examine the evolution of biotech manufacturing
Relate each step to the previous steps, and provide you with a seamless, consistent overview
Provide you with an understanding of basic science, terminology, and common areas of failure in product development
​• Prepare you to improve in your current role, or be ready to enter the biotech field with some foundational understanding

Who Should Attend
This course will benefit anyone who is new to the biotech/biopharma industries, or those who need a refresher. There is no level of prerequisite knowledge or understanding necessary to attend. Additionally, this course will be of value to those who support
any step within the development process including outside vendors.

Course Instructors:


Dr. Jason Carstens has over 20 years of process development, GMP manufacturing, and CMC project management experience in the biotech industry. Dr. Carstens is currently the Chief Operating Officer and a Principal Consultant at Pluristyx, Inc., an advanced therapy tools and service company that he co‑founded which serves customers in the rapidly growing field of regenerative medicine and cellular therapies. Pluristyx has a line of pluripotent stem cell-based products and also offers contract development, manufacturing, and consulting services. Prior to Pluristyx, Dr. Carstens was VP of Manufacturing and Development at Nohla Therapeutics, a Seattle based cell therapy company developing clinical products from hematopoietic stem cells. Dr. Carstens also spent five years as the Director of Cell Therapy Process Development and Manufacturing at the Fred Hutchinson Cancer Research Center in Seattle. While at Fred Hutch, he worked on a variety of autologous and allogenic cell and gene therapy products including CAR T-cells, TIL, antigen specific T-cells, hematopoietic stem cells, and B-cells for use in human clinical trials. Dr. Carstens also spent 13 years at CMC Biologics as the Director of Upstream Process Development where he was responsible for cell line and cell culture process development supporting manufacture, transfer, and scale-up of more than 50 unique recombinant proteins, antibodies, and biosimilars. Dr. Carstens also has an appointment at the University of Washington as an Affiliate Associate Professor. He earned his PhD in Chemical Engineering from the University of California at Berkeley and a BS in Chemical Engineering from the University of Washington.

Dr Ben Fryer is the CEO and co-founder of Pluristyx Inc. providing GMP pre-expanded pluripotent stem cells, contract development services, and consultancy for groups and company developing cell and tissue therapies. Ben has almost 25 years of experience as a leader and scientist in large pharma, academia, and start-up companies developing combination biopharmaceutical products and cell therapies. He has worked to generate GMP/ clinical grade pluripotent stem cells from early banking through large scale expansion using scalable, closed-loop, suspension reactor processes to manufacture cell therapies for diabetes and heart disease. Ben is an inventor on multiple issued patents and patent applications including a bioreactor based, stem cell suspension expansion and differentiation process and a product currently marketed by Thermo-Fisher™ as Nunclon-Vita. Ben earned his BA from Colorado College, his PhD from UPENN, and studied as a post-doctoral fellow in the Howard Hughes Laboratory of M. Celeste Simon at the University of Pennsylvania investigating the role of oxygen sensing and signaling in cancer and stem cell development.

Course Description

Price of Admission

Member

Today’s Price: 1495

Important Dates

Amount

Registration before

Registration before

Registration before

Registration cost

1495

Refund before 2020-04-21

1495

Refund before

Refund Before

Non-Member

Today’s Price: 1995

Important Dates

Amount

Registration before

Registration before

Registration before

Registration cost

1995

Refund before 2020-04-21

1995

Refund before

Refund Before

Registration Closed